Abstract: Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.

Abstract: This disclosure relates to identity verification. In one aspect, a method includes obtaining verification information during a user application session of a user with an application component subsequent to a verification triggering request to perform identity verification on the user. A determination is made whether the verification information satisfies a first identity verification-free condition. When the verification information satisfies the first identity verification-free condition, an identity verification-free operation that does not include identity verification of the user is performed. When the verification information fails to satisfy the first identity verification-free condition, an identity verification process is performed to verify an identity of the user.

Abstract: Dosing regimens for the treatment of coagulation disorders using anti-TFPI antibodies are provided. The methods comprises administering to a subject in need there of an initial dose of about 50 mg to 500 mg of an anti-TFPI antibody or antigen-binding fragment thereof.

Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.

Abstract: This application discloses a housing assembly, including a housing, a decorating part, and an adhesive assembly. The housing is provided with a through hole. The decorating part includes a substrate and a decorating ring protruding from the substrate. An air hole is disposed on the substrate. The air hole is located on an outer side of the decorating ring. The decorating ring is at least partially accommodated in the through hole. A gap is formed between an outer peripheral side surface of the decorating ring and a hole wall of the through hole. The adhesive assembly is attached between the substrate and the housing in a sealed manner. The adhesive assembly is disposed around the decorating ring and the air hole, and a channel is formed between the adhesive assembly and the outer peripheral side surface of the decorating ring.

Abstract: A method includes: training a prediction model with sample data; obtaining user information of a user as an input feature to the prediction model; predicting, using the prediction model according to a set of determination conditions, whether the user has forgotten a payment password associated with a payment application; and in response to predicting that the user has forgotten the payment password and detecting the user logging in the payment application with a login password different from the payment password, displaying a user interface for directing the user to a payment password resetting interface for resetting the payment password.

Abstract: There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).

Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: This application discloses a housing assembly, including a housing, a decorating part, and an adhesive assembly. The housing is provided with a through hole. The decorating part includes a substrate and a decorating ring protruding from the substrate. An air hole is disposed on the substrate. The air hole is located on an outer side of the decorating ring. The decorating ring is at least partially accommodated in the through hole. A gap is formed between an outer peripheral side surface of the decorating ring and a hole wall of the through hole. The adhesive assembly is attached between the substrate and the housing in a sealed manner. The adhesive assembly is disposed around the decorating ring and the air hole, and a channel is formed between the adhesive assembly and the outer peripheral side surface of the decorating ring.

Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Abstract: There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).

Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.

Abstract: A method includes: training a prediction model with sample data; obtaining user information of a user as an input feature to the prediction model; predicting, using the prediction model according to a set of determination conditions, whether the user has forgotten a payment password associated with a payment application; and in response to predicting that the user has forgotten the payment password and detecting the user logging in the payment application with a login password different from the payment password, displaying a user interface for directing the user to a payment password resetting interface for resetting the payment password.

Abstract: This disclosure relates to identity verification. In one aspect, a method includes obtaining verification information during a user application session of a user with an application component subsequent to a verification triggering request to perform identity verification on the user. A determination is made whether the verification information satisfies a first identity verification-free condition. When the verification information satisfies the first identity verification-free condition, an identity verification-free operation that does not include identity verification of the user is performed. When the verification information fails to satisfy the first identity verification-free condition, an identity verification process is performed to verify an identity of the user.

Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.

Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.

Abstract: A method includes: training a prediction model with sample data; obtaining user information of a user as an input feature to the prediction model; predicting, using the prediction model according to a set of determination conditions, whether the user has forgotten a payment password associated with a payment application; and in response to predicting that the user has forgotten the payment password and detecting the user logging in the payment application with a login password different from the payment password, displaying a user interface for directing the user to a payment password resetting interface for resetting the payment password.

Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.